logo
Don't get overwhelmed by 10,000 steps. Here's how many you may really need

Don't get overwhelmed by 10,000 steps. Here's how many you may really need

CTV News24-07-2025
Walking is a good measure of activity level, but it is not the only way to get good movement. (Pablo Rogat's Photostream/via CNN Newsource)
Does the popular activity benchmark of walking 10,000 steps a day feel like too distant of a goal? Don't worry, you can get health benefits just by moving a little more than you already are, new research has found.
When possible, aiming for 7,000 steps a day is a good objective, said lead study author Dr. Melody Ding, professor of public health at the University of Sydney.
Ding and a team of researchers reviewed 31 different studies on the impacts of step count on health markers, including cardiovascular disease, dementia, type 2 diabetes, cancer, depressive symptoms and early death, according to the study published Wednesday in the journal The Lancet Public Health.
Compared with people who got 2,000 steps a day, which researchers considered the minimal possible step count for adults, people who took 7,000 daily steps had a 47% lower risk of death from all causes. The more active adults also had a 25% lower risk of cardiovascular disease and a 38% lower risk of dementia.
Many people who use fitness trackers see 10,000 steps as a sign they are getting enough movement in a day, but that number is not based on good evidence, said Dr. Sean Heffron, assistant professor of medicine at New York University Langone Health and NYU Center for the Prevention of Cardiovascular Disease. He was not involved in the research.
Aiming for 10,000 steps likely originated from a marketing campaign for an early pedometer manufactured in Japan by Yamasa Clock and Instrument Company that was called Manpo-kei, or '10,000 steps meter' in Japanese, according to a 2019 study.
Cardiologist Dr. Martha Gulati said she is usually skeptical when the benchmark is such a nice round number. Gulati was also not involved in the research.
However, it is clear from this study and the existing data that moving more is fundamental for good health and is usually a sound idea, Heffron said.
'More than 7k doesn't do harm, and may even offer some additional benefits,' Ding said in an email. 'If one is already very active and doing 10+k a day, they definitely don't need to hold back and go back to 7k!'
Why steps matter
The study is a meta-analysis, which analyzes evidence across many studies and is one of the highest-quality kinds of research for making clinical recommendations, Heffron said.
Measuring step counts as the recent study did is important not because walking is the only activity that matters, but rather because it is a good way to get a fairly accurate estimate of overall exercise levels, said Gulati, director of preventive cardiology at Cedars-Sinai Medical Center in Los Angeles.
If a patient tells her they did half an hour of exercise, Gulati has to not only trust that they estimated the time accurately but also guess at the intensity of that time spent exercising, she said. On the other hand, if a patient is wearing a tracking device that said they walked 5 miles, that impact is clear whether they walked it, ran it, did it in one go or broke it up, she added.
Unfortunately, many people are quite sedentary, but the baseline for human bodies is to be active, Heffron said. It makes sense that moving less is linked to more health problems.
'The less you move, the less your muscles get engaged, the less exerkines, which are these special chemicals that are released with muscle contractions that benefit levels of inflammation, benefit blood vessel health, but also improve insulin sensitivity and improve blood pressure, and probably have some impact on cognitive function,' he said. 'As there's less of that movement, the rates of all the detrimental conditions increase.'
Physical activity also improves muscular strength, which can help protect against falls and fractures, Gulati said. From a cardiovascular perspective, exercise is linked to lower blood pressure, improved cholesterol and a better response to insulin, she added.
You don't need a gym to get moving
Most Americans could stand to move more, Gulati said. For people who aren't moving much, aiming for 7,000 steps a day may seem like a lot, but just getting started makes a big difference.
'Accumulating daily steps offers a broad range of health benefits. Even low step counts, such as 4k, offers health benefits than lower step counts,' Ding said in an email.
The biggest bang for your buck in terms of your health comes from going from no exercise to adding any movement –– and then gradually building up to more regular activity from there, Heffron added.
Maybe walking isn't your favorite way to get moving. Do things you enjoy, such as dancing, gardening, playing pickleball or hiking with a friend, Heffron said. Getting to the gym and dedicating a block of time to activity may not always be feasible, so he recommends finding ways in your day to add in a little bit more movement.
You can get up every hour at work for a five-minute walk, which incorporates 45 minutes of activity in your day, he said. If you take the bus or subway, getting off a stop or two early and walking the rest of the way can also help you meet your fitness goals.
'It will add a few minutes onto your commute, but every one of those minutes is going to be involved in physical activity,' Heffron said. 'That all adds up little by little over the course of a day and week.'
Getting more steps, however, may not be the best guideline for everyone, particularly those who are limited in their capacity to walk, Ding added.
For seated exercises, try hand cycling or chair exercises with or without weights, Bishnu Pada Das, a certified personal trainer based in Kolkata, India, said in a previous CNN story.
By Madeline Holcombe, CNN
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency
ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency

Globe and Mail

timea day ago

  • Globe and Mail

ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency

Intuitive Surgical 's ISRG Ion platform continues to build momentum, posting a robust 52% year-over-year improvement in procedures (to approximately 35,000) for second-quarter 2025. However, the real story lies beneath the headline growth — system utilization for Ion increased 8% year over year, a critical metric that underscores the company's sharpened focus on workflow optimization and operational efficiency. While system placements dipped to 54 units from 74 a year ago, management remains committed to scaling Ion's usage within its existing installed base. The emphasis is now on enhancing procedural workflows, streamlining clinical adoption and optimizing product costs — all aimed at accelerating Ion's path to profitability. Intuitive Surgical's near-term priorities for Ion include bolstering utilization growth in the United States, while strategically expanding into international markets, notably with first commercial procedures completed in Australia and Korea. As competition intensifies in the robotic-assisted bronchoscopy space, Ion's growing procedural throughput offers a key competitive edge. Higher utilization not only improves return on investment for hospitals but also enhances recurring revenue streams through instrument and accessory sales. Moreover, as ISRG navigates macroeconomic challenges and tariff pressures, workflow efficiency gains and product cost optimizations in Ion could serve as vital levers to protect margins. Given the growing demand for minimally invasive lung biopsy solutions, Ion's capacity to improve procedural throughput and drive operational excellence will be pivotal. The platform's 8% utilization growth may seem incremental, but in a high-mix capital equipment business, such gains could compound significantly over time, enhancing both customer stickiness and long-term value proposition. Investors should closely watch how workflow enhancements translate into higher adoption rates, especially as Intuitive Surgical scales Ion across new geographies and care settings. Competitive Snapshot Stryker 's SYK Mako platform continues to gain traction, with management highlighting strong global utilization growth alongside record installations in second-quarter 2025. As hospitals maximize their existing Mako systems, the surge in procedure volumes is driving higher recurring revenues through consumables and software services. This utilization-driven growth is increasingly important as Stryker navigates tariff pressures and cost headwinds. With expanded applications like hip revision, spine, and soon shoulder procedures, Mako's procedural throughput is poised to accelerate further, enhancing the platform's long-term revenue visibility and margin resilience. Mako is quietly becoming Stryker's high-value recurring revenue engine. Zimmer Biomet 's ZBH ROSA robotics platform saw ongoing adoption in knee procedures, but results were more muted. While ROSA volume-based placements contributed to a mix shift versus outright sales, ROSA was mentioned as central to ZBH's robotic strategy in 2025. The company emphasized the growing uptake of cementless knee and hip implants, including the Oxford Partial Cementless Knee, which complements robotic workflows. Though specific ROSA installation figures weren't disclosed, the system remains integral to ZBH's ASC and digitization strategy. Management cited increased commercial focus and expanded surgical capabilities as key growth drivers, but acknowledged tariffs and ongoing pressure on operating margins as near-term headwinds. ISRG's Price Performance, Valuation and Estimates Shares of ISRG have lost 7.4% in the year-to-date period compared with the industry 's decline of 10.7%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 55.05, above the industry average. But, it is still lower than its five-year median of 72.26. ISRG carries a Value Score of D. The Zacks Consensus Estimate for Intuitive Surgical's 2025 earnings implies an 11.3% rise from the year-ago period's level. The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia
Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

National Post

time2 days ago

  • National Post

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

Article content SMITHS FALLS, Ontario — Canopy Growth Corporation ('Canopy Growth' or the 'Company') (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company's medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Article content Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES' top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. Article content 'Adding 7ACRES to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options,' said Andrew Bevan, SVP, Global Medical. 'With recent improvements to our global supply chain, we're positioned to deliver these strains with consistent quality and reliable access to patients in Australia.' Article content 'Global medical is one of Canopy Growth's largest commercial opportunities,' said Luc Mongeau, Chief Executive Officer. 'Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform.' Article content The introduction of 7ACRES complements Canopy Growth's existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth's focus on building a scalable medical platform across international markets. Article content About Canopy Growth Article content Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Article content Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Article content Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology. Article content At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. Article content Article content Article content Article content Contacts Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store